Search results
Results from the WOW.Com Content Network
Over-expression is also known to occur in ovarian, [19] stomach, adenocarcinoma of the lung [20] and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma, [21] [22] e.g. HER2 is over-expressed in approximately 7-34% of patients with gastric cancer [23] [24] and in 30% of salivary duct carcinomas.
Though incidence and mortality of gastric cancer has declined in many countries over the past 50 years, there has been an increase in occurrences of gastric SRCC-type cancers. [ 5 ] SRCC tumors grow in characteristic sheets, which makes diagnosis using standard imaging techniques, like CT and PET scans , less effective.
] The highest rate of stomach cancer was in Mongolia, at 28 cases per 100,000 people. [105] [unreliable source?] In the United Kingdom, stomach cancer is the 15th most-common cancer (around 7,100 people were diagnosed with stomach cancer in 2011), and it is the 10th most-common cause of cancer-related deaths (around 4,800 people died in 2012 ...
The American Cancer Society estimates that nearly 27,000 new cases of stomach cancer will be diagnosed this year, though the disease is still relatively rare: It makes up around 1.5% of new ...
The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer. [6]
Cancer of the stomach, also called gastric cancer, is the fourth-most-common type of cancer and the second-highest cause of cancer death globally. [2] Eastern Asia (China, Japan, Korea, Mongolia) is a high-risk area for gastric cancer, and North America, Australia, New Zealand and western and northern Africa are areas with low risk. [5]
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [30] [27] [31] [32] It is specifically used for cancer that is HER2 receptor positive. [30] It may be used by itself or together with other chemotherapy medication. [30]
a phase III trial for HER2+ gastric cancer compares T-DM1 to physician's choice of taxane (docetaxel or paclitaxel). [35] On 22 October 2015, Roche and co-developer ImmunoGen disclosed that trastuzumab emtansine had failed to meet its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2 -positive ...